Noticias de RXRX_US

Noticias del mercado

Últimas noticias sobre RXRX_US — 174 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: RXRX_US ✕ 174 resultados
14/05/2026 RXRX_US — Yahoo Finance ES ← EN
Recursion Pharmaceuticals (RXRX): 10 acciones de centavo incomparables para comprar ahora

Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now

14/05/2026 RXRX_US — Investing.com Nigeria ES ← EN
Transcripción de la llamada de resultados: Recursion Pharmaceuticals supera las EPS, los ingresos no alcanzan el primer trimestre de 2026

Earnings call transcript: Recursion Pharmaceuticals beats EPS, revenue miss Q1 2026

14/05/2026 RXRX_US — TradingView ES ← EN
El precio objetivo de 12 meses de las acciones de Recursion Pharmaceuticals, Inc. se elevó a $ 6,64, lo que implica un aumento del 118 %

Recursion Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $6.64, Implies 118% Upside

13/05/2026 RXRX_US — Seeking Alpha
Recursion Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:RXRX) 2026-05-13

2026-05-13. La siguiente presentación de diapositivas fue publicada por Recursion Pharmaceuticals, Inc.

12/05/2026 RXRX_US — Insider Monkey
5 Unrivaled Penny Stocks to Buy Now
12/05/2026 RXRX_US — Investing.com ES ← EN
Transcripción de la llamada de resultados: Recursion Pharmaceuticals supera las EPS, los ingresos no alcanzan el primer trimestre de 2026

Earnings call transcript: Recursion Pharmaceuticals beats EPS, revenue miss Q1 2026

12/05/2026 RXRX_US — Investing.com ES ← EN
Transcripción de la llamada de resultados: Recursion Pharmaceuticals supera las EPS, los ingresos no alcanzan el primer trimestre de 2026

Earnings call transcript: Recursion Pharmaceuticals beats EPS, revenue miss Q1 2026

12/05/2026 RXRX_US — Stock Titan
State Street (RXRX) discloses 28.49M-share, 5.5% stake in Recursion
12/05/2026 RXRX_US — Sahm
Why Recursion Pharmaceuticals (RXRX) Is Down 7.4% After Founder Exit And Deepening FDA Talks
10/05/2026 RXRX_US — Sahm
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Recent Clinical And Cost Management Updates
08/05/2026 RXRX_US — Investing.com ES ← EN
El director de Recursion Pharmaceuticals, Christopher Gibson, vende 134.800 dólares Por Investing.com

Recursion Pharmaceuticals director Christopher Gibson sells $134,800 By Investing.com

08/05/2026 RXRX_US — Investing.com ES ← EN
El director de Recursion Pharmaceuticals, Christopher Gibson, vende 134.800 dólares Por Investing.com

Recursion Pharmaceuticals director Christopher Gibson sells $134,800 By Investing.com

08/05/2026 RXRX_US — Investing.com
Recursion Pharmaceuticals director Christopher Gibson sells $134,800
08/05/2026 RXRX_US — Investing.com ES ← EN
El director de Recursion Pharmaceuticals, Christopher Gibson, vende 134.800 dólares

Recursion Pharmaceuticals director Christopher Gibson sells $134,800

08/05/2026 RXRX_US — Stock Titan
Recursion (NASDAQ: RXRX) director sells, gifts and converts shares
08/05/2026 RXRX_US — Sahm
Recursion’s AI Drug Programs Show Early Clinical Progress And Valuation Gap
08/05/2026 RXRX_US — Insider Monkey
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2026 Earnings Call Transcript
07/05/2026 RXRX_US — TipRanks ES ← EN
Recursion Pharmaceuticals equilibra las victorias iniciales y la pasarela

Recursion Pharmaceuticals Balances Early Wins and Runway

07/05/2026 RXRX_US — Investing.com ES ← EN
El director de Recursion Pharmaceuticals, Blake Borgeson, vende acciones por valor de 105.600 dólares

Recursion Pharmaceuticals director Blake Borgeson sells $105,600 in stock

07/05/2026 RXRX_US — Investing.com ES ← EN
El director de Recursion Pharmaceuticals, Blake Borgeson, vende acciones por valor de 105.600 dólares Por Investing.com

Recursion Pharmaceuticals director Blake Borgeson sells $105,600 in stock By Investing.com

Página 1 de 9

keyboard_arrow_up